INvestigation on Routine Follow-up in CONgestive HearT FAilure Patients with Remotely Monitored Implanted Cardioverter Defibrillators SysTems (InContact)

Claudius Hansen 1*, Christian Loges 2, Karlheinz Seidl 3, Frank Eberhardt 4, Herbert Tröster 5, Krum Petrov 6, Gerian Grönefeld 7, Peter Bramlage 8, Frank Birkenhauer 9 and Christian Weiss 10

Abstract

Background: In heart failure (HF) patients with implantable cardioverter defibrillators (ICD) or cardiac resynchronisation therapy defibrillators (CRT-D), remote monitoring has been shown to result in at least non-inferior outcomes relative to in-clinic visits. We aimed to provide further evidence for this effect, and to assess whether adding telephone follow-ups to remote follow-ups influenced outcomes.

Methods: InContact was a prospective, randomised, multicentre study. Subjects receiving quarterly automated follow-up only (telemetry group) were compared to those receiving personal physician contact. Personal contact patients were further divided into those receiving automated follow-up plus a telephone call (remote+phone subgroup) or in-clinic visits only.

Results: Two hundred and ten patients underwent randomisation (telemetry n = 102; personal contact n = 108 [remote+phone: n = 53; visit: n = 55]). Baseline characteristics were comparable between groups and subgroups. Over 12 months, 34.8% of patients experienced deterioration of their Packer Clinical Composite Response, with no significant difference between the telemetry group and personal care (p > 0.999), remote+phone (p = 0.937) or visit (p = 0.940) patients; predefined non-inferiority criteria were met. Mortality rates (5.2% overall) were comparable between groups and subgroups (p = 0.832/p = 0.645), as were HF-hospitalisation rates (11.0% overall; p = 0.605/p = 0.851). The proportion of patients requiring ≥1 unscheduled follow-up was nominally higher in telemetry and remote+phone groups (42.2 and 45.3%) compared to the visit group (29.1%). Overall, ≥1 ICD therapy was delivered to 15.2% of patients.

Conclusion: In HF patients with ICDs/CRT-Ds, quarterly remote follow-up only over 12 months was non-inferior to regular personal contact. Addition of quarterly telephone follow-ups to remote monitoring does not appear to offer any clinical advantage.

Trial registration: clinicaltrials.gov: NCT01200381 (retrospectively registered on September 13th 2010).

Keywords: Heart failure, Implantable cardioverter defibrillator, Cardiac resynchronisation therapy defibrillator, Remote monitoring, Packer heart failure clinical composite response

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Heart failure (HF) represents a substantial health burden, affecting approximately 26 million people on a global scale and accounting for 1–2% of all hospitalisations in Europe and America [1]. In patients with HF that cannot be effectively managed through medication alone, an implantable cardioverter defibrillator (ICD) or cardiac resynchronisation therapy defibrillator (CRT-D) is commonly indicated [2, 3].

Remote monitoring (RM) of implanted devices has been shown to have a number of advantages over exclusive in-clinic follow-up [4]. Firstly, it facilitates assessment of treatment regimens and optimisation of device functionality without the need for regular outpatient visits [4–6]. This reduces healthcare costs, issues surrounding appointment scheduling, and transportation costs for patients living in remote areas [7], and has been suggested to result in better adherence to follow-up [8]. Secondly, RM may encourage patients to take more responsibility for their own health status, and provide constant peace-of-mind that their device is functioning as intended [9, 10]. Indeed, RM can provide invaluable data for the early identification of clinically important irregularities, such as low battery output, device/lead faults, arrhythmias, and atrial fibrillation [11–14]. This has been demonstrated not only to allow timely prevention of clinical emergencies and mortality, but also to reduce the incidence of inappropriate device interventions [4, 6, 14–21]. Thus, the frequency of cardiovascular hospitalisation and long-term healthcare resource expenditure may be reduced [20, 22–24].

Given the available evidence, the Heart Rhythm Society (HRS) currently recommends that, where possible, use of remote care systems to monitor and interrogate implantable cardiac devices should be used in place of regular in-clinic visits, with a face-to-face evaluation taking place at least once every 12 months [11]. However, the value of supporting remote follow-ups with additional telephone contact has not yet been assessed.

In the present analysis, we aimed to provide more evidence that quarterly automated follow-ups are non-inferior to follow-ups which involve personal physician contact in HF patients with recently implanted ICD/CRT-D devices over 12 months. Secondly, we aimed to determine whether the type of physician contact affected outcomes. Of particular interest was whether the addition of quarterly physician telephone calls to remote follow-ups improved outcomes relative to both automated follow-ups only and traditional in-clinic visits.

Methods
INvestigation on Routine Follow-up in CONgestive HearT FAilure Patients With Remotely Monitored Implanted Cardioverter Defibrillators SysTems (InContact) was a prospective, randomised, multicentre study conducted at 17 sites across Germany (see center list at end of article). The first patient was enrolled in February 2010 and study completion occurred in March 2014. The protocol was approved by the relevant ethics committees and the study was carried out in accordance with the Declaration of Helsinki 1964 and its amendments. All patients provided written informed consent.

Patients and study groups
Only patients with ICD/CRT-D implantation indications consistent with guidelines (new device, generator replacement, or upgrade) were eligible for the present study. Additional inclusion criteria were: age ≥18 and < 80 years; ejection fraction ≤35%; New York Heart Association (NYHA) class I–III; and sufficient home infrastructure to support the use of a Merlin@home™ transmitter. Patients were excluded from the study if they had second-degree Mobitz type II or third-degree atrioventricular block; severe renal insufficiency; a life expectancy < 12 months; were pregnant; or were participating in a simultaneous study with an active therapy arm. Patients who had experienced a myocardial infarction or undergone a coronary angiography in the 3 months prior to enrolment were also excluded.

Following ICD/CRT-D implantation, patients were randomised in a 1:1 ratio into two study arms: those who were to receive quarterly personal contact with a physician (personal contact group) plus RM, and those who were to receive quarterly automated follow-up via Merlin.net only (telemetry group). Personal contact patients were further randomised into two subgroups: quarterly personal telephone calls with a physician/supporting nurse (remote+phone group), or quarterly in-clinic visits only (visit group). All of these groupings applied to the 12-month period between the first and thirteenth month after implantation. Regardless of study group, daily automatic alarm checks were activated for all patients throughout the study period.

Study visits and documentation
A full medical history was taken for each patient prior to the day of ICD/CRT-D implantation (baseline). Prior to hospital discharge (PHD), quality of life (QoL) was assessed using the Minnesota Living with Heart Failure Questionnaire (MLHFQ; a self-administered, disease-specific questionnaire composed of 21 items, each with a 6-point scale [0 = no impact of HF on QoL, 5 = a great deal of impact]) [25]. The correct installation of the Merlin@home™ transmitter was verified within the first month post-intervention. Patients were provided with appropriate information on how to use their transmitter device. Quarterly scheduled sessions and device checks were set up by the clinic.
All patients attended an in-clinic visit 1 month (± 14 days) and 13 months (± 30 days) after ICD/CRT-D implantation, at which their Packer Heart Failure Clinical Composite Response score (Packer score) was determined, medication recorded, and QoL (MLHFQ) assessed. ICD/CRT-D function was then assessed for all patients at 4 and 7 months (± 14 days), either remotely or during the in-clinic appointment (visit group only). An optional follow-up was also carried out at 10 months. Adverse events and ICD/CRT-D measurements were recorded at each time point. Neither in-clinic or telephone interviews were pre-scripted, but were based around the discussion of device data.

Outcome measures
The primary outcome measure was the proportion of patients with a worse Packer score at 13 months relative to their status at 1 month [26]. This composite outcome measure was determined via a stepwise assessment including the following parameters: HF-related death or hospitalisation (worse); deterioration of NYHA class or self-assessed health (worse); improved NYHA class or self-assessed health (improved); none of the above (unchanged).

Secondary outcome measures included the rates of all-cause mortality, HF-hospitalisations, and arrhythmias over the same 12-month period. The number of unscheduled (in-clinic, telephone-based or remote) follow-ups, the proportion of all follow-ups that had disease-relevant findings, and the number of delivered/appropriate ICD therapies were also documented. Changes in QoL between PHD, 1 and 13 months were assessed.

Statistical analysis
The sample size calculation was based on a non-inferiority hypothesis, with a 15% margin for the occurrence of packer endpoint score deterioration at 13-month follow-up assumed. Pre-set values were 5% for the significance level and 80% for the power. A required sample size of 186 patients with complete data sets was calculated for a 1:1 (subgroups: 2:1:1) randomised design. After considering rates of drop out and incomplete data sets (predicted at approximately 20% overall), a total of 210 patients were planned for recruitment.

For continuous variables, a t-test, Wilcoxon signed-rank test or Mann-Whitney U-test were used for two-way comparisons and a Kruskal-Wallis test for three-way comparisons. A chi-square test (or Fisher’s exact test in the case of frequencies <5%) was used for comparing categorical variables. In cases where more than two subgroups were compared and the comparison was significant, Pairwise comparisons of the groups were carried out and p-values were adjusted using the Bonferroni method. To test for the non-inferiority of telemetry compared to personal contact, the 95% confidence interval (CI) for the difference in the proportions of patients with a worsened Packer outcome at 13-month follow-up was calculated. Where the lower bound of this 95% CI exceeded −0.15, automated follow-up was considered non-inferior to personal contact.

Results
The 210 patients initially enrolled in the study were randomised into either the telemetry (n = 102; 49%) or personal contact (n = 108; 51%) group (Fig. 1). Those in the personal contact group were further randomised into the remote+phone (n = 53; 25%) or visit (n = 55; 26%) subgroups.

Baseline characteristics
Baseline characteristics were similar between all groups and subgroups (Table 1). Overall, patients had a mean age of 63.8 years, were predominantly male (84.3%), and had a mean NYHA class of 2.3 ± 0.7 [median 2; range 1–3; 42.9% NYHA III]. The majority had ischemic cardiac disease (59.0%).

Beta-blockers were the most commonly prescribed cardiac drug at baseline (92.9%), followed by amiodarone (11.4%). Only 6.7% of patients were not receiving any HF medication. Diuretics were being taken by 83.8% of the study population, angiotensin-converting enzyme inhibitors by 79.5%, spironolactone by 54.8%, and angiotensin II receptor blockers by 16.2%.

The majority of patients received their ICD in a primary prevention setting (84.8%). The most frequently implanted device was a single chamber ICD (51.4%), followed by a CRT-D (32.4%) and dual-chamber ICD (16.2%). A DF-4 connector was implanted in 71.4% of cases. The most common ICD model was Fortify (36.2%) followed by Current + (18.1%) and Unify (12.4%). All other models were used at a frequency of <7%.

Outcomes at 13 months
Of the patients enrolled, 184 were available for the primary endpoint analysis, 92 (90.2%) in the telemetry and 92 (85.2%) in the personal contact group (remote +phone: 44 patients, 83.0%; visit: 48 patients, 87.3%).

Primary endpoint: Packer heart failure clinical composite response
Overall, 34.8% of patients had a worse Packer score at 13 months relative to 1 month, with 15.2% remaining unchanged and 50.0% experiencing an improvement. This distribution was not significantly different between telemetry and personal care group (p = 0.855) or telemetry, remote+phone and visit groups/subgroups (p = 0.967) (Fig. 2).
When considering only the proportion of patients with a worse packer score, no significant difference was detected between the telemetry compared to personal care group ($p > 0.999$). As the difference between means was 0.000 and the 95% CI (−1.1376 to 0.1376) lower limit greater than the predefined non-inferiority delta (−0.15), non-inferiority of telemetry compared to personal follow up was concluded. Furthermore, no significant difference was found when comparing the telemetry group to the remote+phone subgroup ($p = 0.940$), the telemetry group to the visit subgroup ($p = 0.940$), or the remote+phone and visit subgroups ($p = 0.894$).

Mortality and HF-hospitalisation
During the course of the study, mortality rates were comparable between telemetry and personal contact groups (4.9% vs. 5.6%, $p = 0.832$), and telemetry, remote+phone and visit groups (4.9% vs. 7.5% vs. 3.6%, respectively; $p = 0.645$) (Table 2). Of the 11 deaths which occurred during the course of the study, 4 were from cardiac origin (HF and coronary artery disease), 4 were from non-cardiac origin, and 3 were of “unclear” origin. The origin of death was “unclear” in three of five patients (60%) in the telemetry group compared to none of six (0%) in either of the personal contact groups.

HF-hospitalisation occurred at similar rates in the telemetry and personal contact groups (9.8% vs. 12.0%, $p = 0.605$) (Table 2). This was also the case when comparing telemetry, remote+phone and visit groups/subgroups (9.8% vs. 11.3% vs. 12.7%, $p = 0.851$).

Follow-ups
Overall, 100 patients (47.6%) had at least one relevant finding from at least one ICD/CRT-D follow-up, with no significant differences between the telemetry and personal contact groups ($p = 0.693$) or telemetry, remote+phone and visit groups/subgroups ($p = 0.789$) (Table 3). Again, findings were predominantly medical (82 patients; 39.0% overall), with only 35 patients found to have ICD-related technical findings (16.7% overall). This trend was consistent across all groups and subgroups.

In total, 219 unscheduled follow-ups (102 in-clinic; 106 remote; 11 telephone-based) occurred in 83 patients over a mean period of 369.8 ± 114.7 days. The proportion of patients with at least one unscheduled follow-up was nominally higher in the telemetry compared to personal contact group (42.2% vs. 37.0%, $p = 0.448$), and in the telemetry and remote+phone groups (42.2 and 45.3%) compared to the visit group (29.1%, $p = 0.171$) (Fig. 3). The proportion of patients with physician-initiated unscheduled follow-ups was also nominally higher in telemetry and remote+phone groups (28.4 and 32.1% vs. 18.2%), though did not reach statistical significance. The unscheduled follow-up was considered reasonable in 75.0 and 77.8% of cases in the telemetry and personal contact groups ($p = 0.631$), and 79.6 and 75.6% of remote+phone and visit subgroups ($p$
However, only 51.1% yielded findings, with this proportion nominally higher in the visit subgroup (64.4%) compared to the telemetry (45.8%) and remote+phone (51.9%) group/subgroup (p = 0.104). Findings of a medical nature were generally more common than technical findings (35.2% vs. 9.6%, overall). System revisions were required in six patients (5.9%) in the telemetry group (three

| Table 1 Baseline characteristics |
|---------------------------------|
|                                | Telemetry (N = 102) | Personal contact (N = 108) | Remote + phone (N = 53) | Visit (N = 55) |
| Age (years)                    | 62.5 ± 12.2         | 65.1 ± 10.1                | 64.7 ± 9.1              | 65.4 ± 11.1    |
| Female (%)                     | 17 (16.7)           | 16 (14.8)                  | 7 (13.2)                | 9 (16.4)       |
| Disease parameters             |                    |                            |                         |               |
| LVEF (%)                       | 28.2 ± 7.1          | 28.3 ± 8.9                 | 29.7 ± 10.8             | 26.9 ± 6.5     |
| NYHA class (mean ± SD)         | 2.4 ± 0.6           | 2.3 ± 0.7                  | 2.3 ± 0.7               | 2.3 ± 0.7      |
| NYHA class (median)            | 2 (range 1–3)       | 2 (range 1–3)              | 2 (range 1–3)           | 2 (range 1–3)  |
| NYHA I                         | 7.8                 | 12.0                       | 13.2                    | 10.9           |
| NYHA II                        | 48.0                | 46.3                       | 43.4                    | 49.1           |
| NYHA III                       | 44.1                | 41.7                       | 43.4                    | 40.0           |
| Cardiac disease type           |                    |                            |                         |               |
| None (%)                       | 0 (0.0)             | 1 (0.9)                    | 1 (1.9)                 | 0 (0.0)        |
| Ischemic (%)                   | 58 (56.9)           | 66 (61.1)                  | 30 (56.6)               | 36 (65.5)      |
| Non-ischemic (%)               | 41 (40.2)           | 38 (35.2)                  | 19 (35.8)               | 19 (34.5)      |
| Other (%)                      | 3 (2.9)             | 3 (2.8)                    | 3 (5.7)                 | 0 (0.0)        |
| ICD indication                 |                    |                            |                         |               |
| Primary prevention             | 86 (84.3)           | 92 (85.2)                  | 43 (81.1)               | 49 (89.1)      |
| Secondary prevention           | 16 (15.7)           | 16 (14.8)                  | 10 (18.9)               | 6 (10.9)       |
| Cardiac medication             |                    |                            |                         |               |
| None                            | 5 (4.9)             | 9 (8.3)                    | 4 (7.5)                 | 5 (9.1)        |
| Class 2 (beta-blockers)        | 96 (94.1)           | 99 (91.7)                  | 49 (92.5)               | 50 (90.9)      |
| Class 4                         | 1 (1.0)             | 1 (0.9)                    | 1 (1.9)                 | 0 (0.0)        |
| Amiodarone                      | 12 (11.8)           | 12 (11.1)                  | 5 (9.5)                 | 7 (12.7)       |
| Cardiac medication             |                    |                            |                         |               |
| Diuretics                       | 87 (85.3)           | 89 (82.4)                  | 43 (81.1)               | 46 (83.6)      |
| ACE inhibitors                  | 81 (79.4)           | 86 (79.6)                  | 38 (71.7)               | 48 (87.3)      |
| ARB                             | 18 (17.6)           | 16 (14.8)                  | 10 (18.9)               | 6 (10.9)       |
| Spirinolactone                  | 54 (53.5)           | 61 (56.5)                  | 28 (52.8)               | 33 (60.0)      |
| Device type                     |                    |                            |                         |               |
| ICD Single Chamber             | 57 (55.9)           | 51 (47.2)                  | 27 (50.9)               | 24 (43.6)      |
| ICD Dual Chamber                | 13 (12.7)           | 21 (19.4)                  | 12 (22.6)               | 9 (16.4)       |
| CRT-D                           | 32 (31.4)           | 36 (33.3)                  | 14 (26.4)               | 22 (40.0)      |
| DF-4 connector                  | 73 (71.6)           | 77 (71.3)                  | 36 (67.9)               | 41 (74.5)      |
| MLHQF score PHD                 | 33.6 ± 22.0         | 33.3 ± 22.0                | 33.7 ± 24.7             | 33.0 ± 19.3    |
| MLHQF score at 1 M             | 240 ± 20.3          | 218 ± 19.3                 | 228 ± 23.7              | 20.9 ± 14.2    |

LVEF left ventricular ejection fraction, NYHA New York Heart Association, ICD implantable cardioverter-defibrillator, ACE angiotensin-converting enzyme, ARB angiotensin II receptor blockers, CRT-D cardiac resynchronization therapy implantable cardioverter-defibrillator, MLHQF Minnesota Living with Heart Failure Questionnaire, PHD pre-hospital discharge, 1M 1 month

* Data was missing for 1 patient

= 0.797 also vs. telemetry group) (Table 3).
dislodgements, one myocardial perforation, one planned placement of an epicardial left ventricular lead, and one anticipated perforation of device through skin) and one patient (0.9%) in the personal contact (remote+phone) group (dislodgement and myocardial perforation; \( p = 0.059 \)) (Table 3).

**Arrhythmias and ICD therapies**

Stored tachycardias occurred in 22.9% of the population, with no significant differences between groups (\( p = 0.579 \)) or subgroups (\( p = 0.899 \)) (Table 2). Rates of ventricular fibrillation/tachycardia and supraventricular tachycardia (SVT) were statistically comparable between telemetry and personal contact groups (19.6% vs. 15.7%, \( p = 0.462 \); and 17.6% vs. 10.2%, \( p = 0.117 \), respectively). The same was true for subgroup comparisons.

Overall, at least one ICD therapy was delivered to 32 patients (15.2%) during follow-up, with ATP therapy given to 14.3% and shock to 8.6% of all patients. These trends were consistent across groups and subgroups.

**Functional status and quality of life**

Overall, NYHA class worsened by a mean of 0.08 ± 0.672 between 1 and 13 months (median 2, range 1–3), with no significant differences found for group (\( p = 0.888 \)) or subgroup (\( p = 0.912 \)) comparisons (Table 2). NYHA class worsened in 24.0%, was unchanged in 59.6% and improved in 16.4% of the total population, again without significant differences in distribution between groups (\( p = 0.639 \)) or subgroups (\( p = 0.715 \)).

The overall mean change in MLHFQ score between PHD and 13 months was −9.38, with a mean increment of 1.64 between 1 and 13 months. This trend was consistent across all groups and subgroups, with no significant differences detected (Table 2).

**Discussion**

We aimed to compare the outcomes of HF patients receiving quarterly automated ICD/CRT-D follow-up compared to those receiving personal physician follow-up at the same intervals over 12 months. We further explored the impact of the type of physician contact on outcomes. Given its prior absence in the literature, the effect of adding telephone follow-up to remote follow-up was of particular interest. We found that comparable proportions of the different follow-up groups/subgroups experienced a worsening of their Packer score over the course of the study. The same was true for rates of mortality, HF-hospitalisation, unscheduled follow-ups, and inappropriate ICD therapy. Taking into account the robust comparability of baseline characteristics, our data suggest that a 12-month follow-up programme via a fully automated system is non-inferior to a programme involving regular physician contact. Furthermore, the
addition of telephone follow-ups to quarterly automated follow-ups appears not to produce a clinical advantage, though further corroboratory data would be instructive.

Packer heart failure clinical composite response
Change in Packer score was used as a primary assessment criterion as it is considered to provide a clinically meaningful overview of HF status, encompassing changes in both disease parameters and risk of major clinical events [26, 27]. However, it has been employed in only a few RM studies to date. The 664-patient IN-TIME study used this endpoint to demonstrate that telemonitoring plus standard care resulted in 8.3% fewer patients deteriorating over 12 months compared to those receiving standard care only ($p = 0.013$) [16]. While this did not address the question of whether remote follow-up alone can replace physician follow-up, it did suggest the advantage of combining RM plus personal contact over exclusive face-to-face assessment.

In terms of studies assessing the value of entirely remote follow-ups, only the 16-month EVOLVO study appears to have employed the Packer composite endpoint [28]. This study compared 99 patients exclusively receiving remote follow-up with 101 receiving in-clinic

### Table 2 Secondary outcomes: Packer sub-items, cardiac parameters, and QoL

|                                | Telemetry ($N = 102$) n (%) / mean ± SD | Personal contact All ($N = 108$) n (%) / mean ± SD | Remote + phone ($N = 53$) n (%) / mean ± SD | Visit ($N = 55$) n (%) / mean ± SD | p-value (telemetry vs. personal contact) | p-value (telemetry vs. remote + phone vs. visit) |
|--------------------------------|----------------------------------------|-------------------------------------------------|---------------------------------------------|------------------------------------|------------------------------------------|---------------------------------------------|
| **Packer sub-items**          |                                        |                                                 |                                             |                                    |                                          |                                             |
| Death                         | 5 (4.9)                                | 6 (5.6)                                        | 4 (7.5)                                     | 2 (3.6)                            | 0.832                                    | 0.645                                       |
| Cardiac                       | 1 (20.0)                               | 3 (50.0)                                       | 2 (50.0)                                    | 1 (50.0)                          | 0.259                                    | 0.292                                       |
| Non-cardiac                   | 1 (20.0)                               | 3 (50.0)                                       | 2 (50.0)                                    | 1 (50.0)                          | 0.259                                    | 0.292                                       |
| Origin unclear                | 3 (60.0)                               | 0 (0.0)                                        | 0 (0.0)                                     | 0 (0.0)                           |                                          |                                             |
| HF-hospitalisation$^{b}$      | 10 (9.8)                               | 13 (12.0)                                      | 6 (11.3)                                    | 7 (12.7)                          | 0.605                                    | 0.851                                       |
| NYHA class at 13 M vs. 1 M$^{a}$|                                        |                                                 |                                             |                                    |                                          |                                             |
| Worse                         | 22 (25.3)                              | 19 (22.6)                                      | 7 (17.9)                                    | 12 (26.7)                         |                                          |                                             |
| Unchanged                     | 49 (56.3)                              | 53 (63.1)                                      | 27 (69.2)                                   | 26 (57.8)                         |                                          |                                             |
| Improved                      | 16 (18.4)                              | 12 (14.3)                                      | 5 (12.8)                                    | 7 (15.6)                          |                                          |                                             |
| Change in NYHA class at 13 M vs. 1 M$^{a}$ | −0.07 ± 0.71                          | −0.10 ± 0.63                                   | −0.8 ± 0.62                                 | −0.11 ± 0.65                      | 0.888                                    | 0.912                                       |
| **Self-assessment$^{c}$**     |                                        |                                                 |                                             |                                    |                                          |                                             |
| Worse                         | 8 (9.2)                                | 10 (11.8)                                      | 6 (15.0)                                    | 4 (8.9)                           | 0.582                                    | 0.564                                       |
| Unchanged                     | 24 (27.6)                              | 21 (24.7)                                      | 9 (22.5)                                    | 12 (26.7)                         |                                          |                                             |
| Improved                      | 55 (63.2)                              | 54 (63.5)                                      | 25 (62.5)                                   | 29 (64.4)                         | 0.966                                    | 0.982                                       |
| **Cardiac events**           |                                        |                                                 |                                             |                                    |                                          |                                             |
| Stored tachycardia$^{d}$      | 25 (24.5) / 48 ± 15.6                  | 23 (21.3) / 22 ± 9.0                           | 11 (20.8) / 10 ± 4.5                        | 12 (21.8) / 35 ± 11.8             | 0.579 / 0.431                            | 0.850 / 0.680                               |
| VT/VF$^{d}$                   | 20 (19.6)                              | 17 (15.7)                                      | 8 (15.1)                                    | 9 (16.4)                          | 0.462 / 0.752                            | 0.752 / 0.689                               |
| SVT$^{d}$                     | 2.1 ± 9.1                              | 1.3 ± 6.7                                      | 0.8 ± 3.7                                   | 1.8 ± 8.7                         | 0.409 / 0.689                            | 0.689 / 0.689                               |
| Cardiac decompensations       | 9 (8.8)                                | 9 (8.3)                                        | 5 (9.4)                                     | 4 (7.3)                           | 0.899                                    | 0.915                                       |
| **QoL**                       |                                        |                                                 |                                             |                                    |                                          |                                             |
| Change in MLHFQ score at 13 M vs. PHD | −8.4 ± 20.3                           | −10.5 ± 21.6                                   | −12.1 ± 22.7                                | −9.1 ± 20.8                       | 0.472                                    | 0.724                                       |
| Change in MLHFQ score at 13 M vs. 1 M$^{a}$ | 0.7 ± 16.8                            | 2.7 ± 20.5                                     | 3.0 ± 22.2                                  | 2.4 ± 19.1                       | 0.666                                    | 0.837                                       |

NYHA New York Heart Association, 13 M 13 months, HF heart failure, VF ventricular fibrillation, VT ventricular tachycardia, SVT supraventricular tachycardia, MLHFQ Minnesota Living with Heart Failure Questionnaire, PHD pre-hospital discharge, 1 M 1 month

$^{a}$Data based on non-missing values ($n = 171$)

$^{b}$Data based on non-missing values ($n = 174$)

$^{c}$Data based on non-missing values ($n = 172$)

$^{d}$Percentage of patients / number of tachycardia events
Table 3  Secondary outcomes: follow-ups between months 1 and 13

|                          | Telemetry (N = 102) | Personal contact (N = 108) | Remote+phone (N = 53) | Visit (N = 55) | p-value (telemetry vs. personal contact) | p-value (telemetry vs. remote+phone vs. visit) |
|--------------------------|---------------------|-----------------------------|-----------------------|---------------|-------------------------------------------|---------------------------------------------|
| FU duration (days)       | 372.8 ± 100.3       | 366.9 ± 127.5               | 349.9 ± 147.8         | 384.0 ± 102.0 | 0.689                                     | 0.490                                       |
| Unscheduled FUs          |                     |                             |                       |               |                                           |                                             |
| No. of FUs /patient      | 1.2 ± 2.6           | 0.9 ± 1.8                   | 1.0 ± 1.7             | 0.8 ± 2.0     | 0.550                                     | 0.285                                       |
| Total number             | 120                 | 99                          | 54                    | 45            |                                           |                                             |
| Considered reasonable    | 90 (75.0)           | 77 (77.8%)                  | 43 (79.6)             | 34 (75.6)     | 0.631                                     | 0.797                                       |
| With findings            | 55 (45.8)           | 57 (57.6)                   | 28 (51.9)             | 29 (64.4)     | 0.084                                     | 0.104                                       |
| Medical                  | 40 (33.3)           | 37 (37.4)                   | 17 (31.5)             | 20 (44.4)     | 0.534                                     | 0.335                                       |
| Technical                | 9 (7.5)             | 12 (12.1)                   | 9 (16.7)              | 3 (6.7)       | 0.249                                     | 0.126                                       |
| All FUs                  |                     |                             |                       |               |                                           |                                             |
| Patients with relevant findings at ≥1 FU | 50 (49.0) | 50 (46.3)                | 26 (49.1)             | 24 (43.6)     | 0.693                                     | 0.789                                       |
| Medical                  | 42 (41.2)           | 40 (37.0)                   | 19 (35.8)             | 21 (38.2)     | 0.539                                     | 0.803                                       |
| Technical                | 16 (15.7)           | 19 (17.6)                   | 11 (20.8)             | 8 (14.5)      | 0.711                                     | 0.642                                       |
| Patients with ICD therapy at ≥1 FU | 17 (16.7) | 15 (13.9)                | 7 (13.2)              | 8 (14.5)      | 0.576                                     | 0.839                                       |
| ICD shock                | 9 (8.8)             | 9 (8.3)                     | 4 (7.5)               | 5 (9.1)       | 0.899                                     | 0.792                                       |
| ATP therapy              | 16 (15.7)           | 14 (13.0)                   | 7 (13.2)              | 7 (12.7)      | 0.573                                     | 0.851                                       |
| System revisions         |                     |                             |                       |               |                                           |                                             |
| Patients requiring ≥1    | 6 (5.9)             | 1 (0.9)                     | 1 (1.9)               | 0 (0)         | 0.059                                     | 0.141                                       |
| Mean per patient         | 0.06 ± 0.02         | 0.01 ± 0.10                 | 0.02 ± 0.14           | 0.00 ± 0.00   | 0.046                                     | 0.118                                       |

FU follow-up, ICD implanted cardioverter-defibrillator, ATP anti-tachycardia pacing

Fig. 3  Unscheduled follow-ups between 1 and 13 months. Legend: unsched., unscheduled; FU, follow-up. The percentages displayed in the table and graph are proportional to the total number of patients within the respective group/subgroup that had ≥1 unscheduled follow-up. The three initiation types are not exclusive and any one patient may be represented by multiple bars. The distribution of initiation types was not significantly different between telemetry vs. personal care or telemetry vs. remote+phone vs. visit groups/subgroups. Follow-ups could be in-house or remote.
follow-up only, and found no significant difference in the proportion of patients with a worse Packer score at 16 months relative to baseline (34% vs. 36%, respectively). Concurrently, 35% of all patients in the present study were found to have experienced a deterioration in Packer score between 1 and 13 months, with this applying to a comparable proportion of telemetry and personal contact (including visit) patients. Furthermore, the non-inferiority of the entirely remote approach was statistically indicated according to the predefined criteria. Thus, our data support previous findings that automated follow-up regimes are non-inferior to in-clinic follow-up regimes in terms of composite response. In addition, our data go further, indicating for the first time that addition of a telephone call to quarterly remote follow-ups may not provide any significant advantage over RM alone. In light of this, current HRS guidelines appear to be appropriate [11], though further validation of our findings in larger-scale studies is required.

Mortality
There was no difference in all-cause mortality at 12 months in the telemetry compared to the visit group (4.9% vs. 3.6%, respectively). This is in line with other randomised control trials (RCTs), such as the MORE-CARE (9.2% vs. 7.9%, $p = 0.594$) and TELEcart (7.9% vs. 8.9%, $p = 0.54$) studies and a large-scale meta-analysis comparing RM to outpatient follow-up (odds ratio [OR] 0.83, 95% CI 0.58–1.17, $p = 0.285$) [17]. Conversely, several observational studies have identified lower mortality rates in patients receiving telemonitoring compared to those followed up in-house [15, 18]. Perhaps the most convincing of these is ALTITUDE, which compared 10,272 matched ICD and CRT-D patients with or without remote network follow-up over 5 years post-implant [15]. The risk of death was found to be halved by application of RM (ICD: hazard ratio [HR] 0.56, 95% CI 0.47–0.67, $p < 0.001$; CRT-D: HR 0.45, 95% CI 0.39–0.53, $p < 0.001$); however, follow-up modality was decided by the treating physician based on device availability and logistics, introducing a probable bias. Furthermore, patients may receive more rigorous assessment in the context of a RCT, resulting in a higher quality of in-house care provision. Regardless of the cause, it is important to note that findings from RCTs, however robust, may not directly translate into a real-world context. This should be taken into consideration when reflecting upon the finding that there was no significant difference in mortality rates between telemetry and remote+phone groups, even when stratified by cause of death. While our analysis was explorative, this once more indicates that addition of telephone contact to remote follow-up may not be advantageous for reducing fatalities, at least in the context of an RCT. Of interest is the finding that the cause of death was “unclear” in 60% of telemetry patients compared to none of the personal contact patients, suggesting that the availability of certain information may be lost through entirely remote management. Nonetheless, further investigation of the present findings through real-world observational registries may be informative.

HF-hospitalisations
No significant differences were found between groups or subgroups with respect to the frequency of HF-hospitalisations. Again, this was consistent with previous findings from RCTs, including CONNECT and EVOLVO [14, 28–30]. These studies reported annual rates ranging from 0.39–0.50 cardiovascular hospitalisations per patient, with no difference between RM and in-clinic groups ($p = 0.99$ and $p = 0.464$ for each study, respectively) [14, 28]. Furthermore, a recently published meta-analysis pooling data from 7 RCTs found no significant reduction in the odds of hospitalisation with RM compared to standard care (OR 0.83; 95% CI 0.63–1.10; $p = 0.196$) [17]; however, it should be noted that this referred to hospitalisation for all-causes. Nonetheless, the apparent lack of impact of telephone contact in addition to remote follow-up on HF-hospitalisation rates in the present study is unsurprising.

Interestingly, observational studies have consistently associated telemetry with a reduction in hospitalisation frequency [12, 23, 24]. Again, this discrepancy is likely due to socioeconomic and geographical bias reflective of real-world trends and applications. Thus, evaluating the effect of RM plus telephone follow-up on HF-hospitalisation rates in a real-world setting may prove interesting. Of note, observational studies have also linked RM to a shorter duration of hospitalisation episodes and lower associated costs [12, 23, 24], with one analysis specifically identifying a reduction in cardiovascular hospitalisation expenditure as the key driver for the cost savings associated with RM [23]. Though these parameters were beyond the scope of the present analysis, they should be borne in mind for future studies evaluating the value of telephone contact as an adjunct to RM.

Unscheduled follow-ups
Though not reaching statistical significance, the proportion of patients who had at least one unscheduled follow-up in the present study was approximately 15% higher in the telemetry and remote+phone groups compared to the visit group. This appears to have been largely driven by more frequent physician-initiated follow-ups. A higher yearly rate of additional follow-ups in remotely monitored patients compared to those regularly attending in-clinic appointments was also noted in TRUST (0.78 vs. 0.50 visits/person/year, $p = 0.009$),
Quality of life
It has been suggested that RM can reduce the inconvenience of attending in-clinic visits and anxiety between follow-ups, resulting in a positive effect on QoL [10]. However, most studies have found it to have no effect on QoL [5, 29], with the exception of the EVOLVO study [28]. Although MLHFQ score fell by approximately 9 points between PHD and 13 months in the present study, indicating an overall improvement in QoL, a minor deterioration between months 1 and 13 occurred in all groups. This deterioration was marginally smaller in the remote+phone group, though this effect was not significant due to the large within-group variations (demonstrated by very large standard deviations). Our data are thus in line with previous evidence that neither automated remote follow-up nor personal contact appear to be superior for improving MLHFQ-measured patient QoL.

Limitations
This was a prospective, randomised multicentre study in Germany with patients being monitored using the Merling/home™ system. We regard this, together with the possible use of different ICD/CRT-D devices, as a particular strength of the study. However, our findings may not be generalizable to patients using other RM systems. In addition, while we endeavoured to ensure consecutive enrolment, this was not always possible; as such, we cannot guarantee the elimination of selection bias. Furthermore, the relevance of medical and technical findings was determined at the physician’s discretion, potentially leading to subjectivity bias. Nevertheless, randomisation ensured that any one physician was treating both RM and personal contact patients, likely resulting in a reasonably uniform impact of such bias across groups and subgroups. Finally, limited patient numbers may have prevented detection of small but significant effects owing to insufficient statistical power. Indeed, initial sample size calculations were performed based on between-group comparisons, with subgroup comparisons thus being suboptimally powered. As such, large-scale observational studies would be informative.

Conclusions
In HF patients with recently implanted ICDs/CRT-Ds, entirely automated remote follow-up is non-inferior to follow-up with personal contact over a period of 12 months. Furthermore, the addition of a telephone call

Arrhythmias and ICD therapies
There were no significant differences between groups and subgroups with respect to cardiac decompensations or number of stored tachycardias. Similarly, a study by Marcantoni et al. designed particularly to explore the effect of RM on supraventricular and ventricular arrhythmias also found no difference in incidence when comparing patients followed remotely to those followed in the clinic [19]. However, the study did report a reduction in associated events in the RM group, explained as due to the earlier detection and pre-emptive treatment of such arrhythmias. ICD therapy (shock or ATP) is associated with an increased risk of mortality and HF deterioration, regardless of its appropriacy [33, 34]. This is thought to be partly due to the negative inotropic consequences of the therapy, which may result in a significant reduction in cardiac index [35–37]. Consequently, avoidance of inappropriate therapy is paramount. In the present study, approximately 15% of patients received ICD therapy over 12 months, with no notable differences across groups or subgroups. This is consistent with the majority of previously published studies [6, 15, 17, 21].
to quarterly automated follow-ups does not appear to be beneficial for improving outcomes, though further studies are necessary to corroborate this finding. Nevertheless, the present study provides additional evidence in support of the safe and effective replacement of regular physician contact with fully-automated follow-up in this patient population.

Center list - Germany

Herz- und Gefäßzentrum am Krankenhaus Neu-Bethlehem Göttingen gGmbH, 37,073 Göttingen; Städtisches Klinikum Lüneburg gGmbH, 21,339 Lüneburg; SLK-Kliniken Heilbronn GmbH Klinikum am Plattenwald, 74,177 Bad Friedrichshall; Klinikum Ingolstadt GmbH, 85,049 Ingolstadt; Evangelisches Krankenhaus Kalk, 51,103 Köln; Marienhospital Stuttgart, 70,199 Stuttgart; Klinikum Sindelfingen-Böblingen gGmbH, 71,065 Sindelfinden; Asklepios Klinik Bad Oldesloe, 23,843 Bad Oldesloe; Evangelisches Krankenhaus Bielefeld gGmbH, 33,617 Bielefeld; Marienhaus Klinikum St. Elisabeth-Krankenhaus, 56,564 Neuwied; Asklepios Klinik St. Georg, 20,099 Hamburg; Universitätsklinikum Essen (AöR), 45,122 Essen; Praxis Dr. med. Balbach / Ruppert, 72,622 Nürtingen.

Abbreviations
ACE: Angiotensin converting enzyme; ARB: Angiotensin receptor blocker; ATP: Antitachycardia pacing; CI: Confidence interval; CRT-D: Cardiac resynchronisation therapy defibrillator; FU: Follow up; HF: Heart failure; HRS: Heart Rhythm Society; ICD: Implantable cardioverter defibrillator; LVEF: Left ventricular ejection fraction; MLHFQ: Minnesota Living with Heart Failure Questionnaire; NYHA: New York Heart Association; PHD: Pre-hospital discharge; QoL: Quality of life; RM: Remote monitoring; SD: Standard deviation; SVT: Supraventricular tachycardia; VF: Ventricular fibrillation; VT: Ventricular tachycardia

Acknowledgements
The authors would like to express their sincere thanks to Rita Omega Ella Abbott (– St. Jude Medical) for providing statistical supervision.

Funding
Abbott (formerly St. Jude Medical, Eschborn, Germany) funded the study. The sponsor was involved in the design of the study, the data collection, the analysis and interpretation of the data and during the revision of the manuscript.

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due to data protection but are available from the corresponding author on reasonable request.

Authors’ contributions
Conception: CH, CL, KS, FH, HT, KP, GG, PB, FB; Design: CH, CL, KS, FH, HT, KP, GG, PB, FB; Acquisition: CH, CL, KS, FH, HT, KP, GG, PB, FB, CW; Interpretaion of data: CH, CL, KS, FH, HT, KP, GG, PB, CW; Drafting the work: CH, PB; Critical revision for important intellectual content: CL, KS, FH, HT, KP, GG, FB, CW; Final approval: CH, CL, KS, FH, HT, KP, GG, PB, FB, CW; Agrees to be accountable: CH, CL, KS, FH, HT, KP, GG, PB, FB, CW. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The protocol was approved by the relevant ethics committees and the study was carried out in accordance with the Declaration of Helsinki 1964 and its amendments. All patients provided written informed consent.

Competing interests
Peter Bramlage has received honoraria relevant to this topic. Frank Birkenhauer is an employee of Abbott. The other authors have no competing interest to declare.

Ethics Committee of the Medical Faculty, University of Göttingen: Göttingen, Lüneburg.
Ethic Committee International Freiburg: Bad Friedrichshall, Cologne, Stuttgart, Sindelfingen, Potsdam, Ludwigsburg, Bielefeld, Essen, Nürtingen.
Ethic Committee of the Bavarian Medical Association: Ingolstadt.
Ethic Committee of the Hamburg Medical Association: Hamburg.
Ethic Committee of the Schleswig Holstein Medical Association: Bad Segeberg, Bad Oldesloe.
Ethic Committee of the Rhineland Palatinate Medical Association: Neuwied.

Consent for publication
Not applicable.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Herz- und Gefäßzentrum am Krankenhaus Neu-Bethlehem, Humboldtstraße 6, 37073 Göttingen, Germany. 2SLK-Kliniken Heilbronn Klinikum am Plattenwald, Bad Friedrichshall, Germany. 3Klinikum Ingolstadt, Ingolstadt, Germany. 4Evangelisches Krankenhaus Kalk, Köln, Germany. 5Marienhospital Stuttgart, Stuttgart, Germany. 6Klinikum Böblingen Standort Sindelfingen, Sindelfingen, Germany. 7Asklepios Klinik Barmbek, Hamburg, Germany. 8Institut für Pharmakologie und Präventive Medizin, Cloppenburg, Germany. 9Abbott - St. Jude Medical GmbH, Eschborn, Germany. 10Städtisches Klinikum Lüneburg gGmbH, Lüneburg, Germany.

Received: 1 December 2017 Accepted: 13 June 2018
Published online: 28 June 2018

References
1. Ambrosy AP, Fonarow GC, Butler J, Chiouchel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(12):1123–33.
2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. AHA/ACC guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–299.
3. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):911–975.
4. Bertini M, Marcantoni L, Toselli T, Ferrari R. Remote monitoring of implantable devices: should we continue to ignore it? Int J Cardiol. 2016;202:368–77.
5. Mabo P, Victor F, Bazin P, Aheer S, Babuty D, Da Costa A, et al. A randomized trial of long-term remote monitoring of pacemaker recipients (the COMPAS trial). Eur Heart J. 2012;33(9):1105–11.
6. Osmera O, Bulava A. The benefits of remote monitoring in long-term care for patients with implantable cardioverter-defibrillators. Neuro Endocrinol Lett. 2014;35(Suppl)1:40–8.
7. Fauquier L, Sadoul N, Kouakam C, Briand F, Chauvin M, Babuty D, et al. Potential cost savings by telemedicine-assisted long-term care of implantable cardioverter defibrillator recipients. Pacing Clin Electrophysiol. 2005;28(Suppl 1):S255–9.
8. Varma N, Michalski J, Stambler B, Pavli BB. Superiority of automatic remote monitoring compared with in-person evaluation for scheduled ICD follow-
up in the TRUST trial - testing execution of the recommendations. Eur Heart J. 2014;35(20):1345–52.
29. Heidbuchel H, Hindricks G, Broadhurst P, Van Enen L, Fernandez-Lozano I, Rivero-Ayerza M, et al. EuroECO (European health economic trial on home monitoring in ICD patients): a provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring. Eur Heart J. 2015;36(3):158–69.
30. Botani G, Da Costa A, Quesada A, Ricci RP, Fava F, Boscolo G, et al. Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORE-CARE multicentre randomized controlled trial. Eur J Heart Fail. 2017;19(2):156–25.
31. Varma N, Epstein AE, Schweikert R, Michalski J, Love CJ. Role of automatic wireless remote monitoring immediately following ICD implant: the Lumos-T reduces Routine office device follow-up study (TRUST) trial. J Cardiovasc Electrophysiol. 2016;27(3):321–6.
32. Varma N, Michalski J, Epstein AE, Schweikert R. Automatic remote monitoring of implantable cardioverter-defibrillator lead and generator performance: the Lumos-T safely RedUceS RoutinE office device follow-up (TRUST) trial. Circ Arrhythm Electrophysiol. 2010;3(5):428–36.
33. Sweeney MO, Sherfese L, DeGroot PJ, Wathen MS, Wilkoff BL. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm. 2010;7(3):533–60.
34. Poole JE, Johnson GW, Helfkamp AS, Anderson J, Callans DJ, Raitt MH, et al. Prognostic importance of defibrillator shocks in patients with heart failure. NEJM. 2008;359(10):1009–17.
35. Tokano T, Bach D, Chang J, Davis J, Souza JJ, Zivin A, et al. Effect of ventricular shock strength on cardiac hemodynamics. J Cardiovasc Electrophysiol. 1998;9(8):791–7.
36. Hazemir-CAN, Shah N, Rao AP, Acosta H, Matsudaira K, Neas BR, et al. Analysis of troponin I levels after spontaneous implantable cardioverter-defibrillator shocks. J Cardiovasc Electrophysiol. 2002;13(2):144–50.
37. Yamaguchi H, Weil MH, Tang W, Kamohara T, Jin X, Biser J. Myocardial dysfunction after electrical defibrillation. Resuscitation. 2003;59(3):428–46.